Literature DB >> 16476979

Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): evolution of coreceptor use varies with pathogenic outcome.

Anna Laurén1, Dalma Vödrös2,1, Rigmor Thorstensson3, Eva Maria Fenyö1.   

Abstract

Coreceptor usage of isolates from 30 cynomolgus macaques infected intrarectally (n=22) or intravenously (n=8) with simian immunodeficiency virus of sooty mangabey origin (SIVsm) was evaluated in U87.CD4 and GHOST(3) cell lines. Based on progression rate, the animals were divided into progressors (18 animals), slow progressors (five animals) and long-term non-progressors (seven animals). There was no difference in how many or which coreceptors were used according to route of infection. All isolates but one used CCR5 for cell entry, and CCR5 was also the major coreceptor in 70 out of 105 isolates tested. In general, early isolates were multitropic, using CCR5, CXCR6 and/or gpr15. Interestingly, CXCR4-using viruses could be isolated on human peripheral blood mononuclear cells (PBMCs), but not on cynomolgus macaque PBMCs, suggesting that human PBMCs select for variants with CXCR4 use. Even though CXCR4-using SIV isolates have been reported rarely, we could recover CXCR4-using viruses from 13 monkeys. CXCR4 use either appeared early during the acute phase of infection and disappeared later or only appeared late in infection during immunodeficiency. Surprisingly, one late isolate from a progressor monkey did not use CCR5 at all and used the CXCR4 receptor with high efficiency. The ability to use many different receptors decreased over time in long-term non-progressor monkeys, whilst the majority of progressor monkeys showed broadening of coreceptor use, stable coreceptor use or fluctuation between the different coreceptor-usage patterns. The results indicate that, in the infected host, evolution of SIV coreceptor usage occurs, involving changes in the mode of coreceptor use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476979     DOI: 10.1099/vir.0.81408-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection.

Authors:  Jacob T Minang; Matthew T Trivett; Eugene V Barsov; Gregory Q Del Prete; Charles M Trubey; James A Thomas; Robert J Gorelick; Michael Piatak; David E Ott; Claes Ohlen
Journal:  Virology       Date:  2010-10-28       Impact factor: 3.616

2.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

3.  Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody.

Authors:  Brian J Willett; Martin Kraase; Nicola Logan; Elizabeth L McMonagle; Ayman Samman; Margaret J Hosie
Journal:  Retrovirology       Date:  2010-04-26       Impact factor: 4.602

4.  A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo.

Authors:  Nadeene E Riddick; Emilia A Hermann; Lamorris M Loftin; Sarah T Elliott; Winston C Wey; Barbara Cervasi; Jessica Taaffe; Jessica C Engram; Bing Li; James G Else; Yingying Li; Beatrice H Hahn; Cynthia A Derdeyn; Donald L Sodora; Cristian Apetrei; Mirko Paiardini; Guido Silvestri; Ronald G Collman
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

5.  CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates.

Authors:  Anna Laurén; Elzbieta Vincic; Hiroo Hoshino; Rigmor Thorstensson; Eva Maria Fenyö
Journal:  Retrovirology       Date:  2007-07-23       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.